Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond
Authors
Keywords
-
Journal
PHARMACEUTICAL STATISTICS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-11-27
DOI
10.1002/pst.1917
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- On the propensity score weighting analysis with survival outcome: Estimands, estimation, and inference
- (2018) Huzhang Mao et al. STATISTICS IN MEDICINE
- Outcome pre-specification requires sufficient detail to guard against outcome switching in clinical trials: a case study
- (2018) Brennan C. Kahan et al. Trials
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Per-Protocol Analyses of Pragmatic Trials
- (2017) Miguel A. Hernán et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
- (2017) Robert Marcus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- A framework for the design, conduct and interpretation of randomised controlled trials in the presence of treatment changes
- (2017) Susanna Dodd et al. Trials
- A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease
- (2016) David J. M. McGhee et al. BMC Neurology
- Seeking harmony: estimands and sensitivity analyses for confirmatory clinical trials
- (2016) Devan V Mehrotra et al. Clinical Trials
- Statistical issues in the analysis of adverse events in time-to-event data
- (2016) Arthur Allignol et al. PHARMACEUTICAL STATISTICS
- Disentangling estimands and the intention-to-treat principle
- (2016) Ann-Kristin Leuchs et al. PHARMACEUTICAL STATISTICS
- Estimands in clinical trials - broadening the perspective
- (2016) Mouna Akacha et al. STATISTICS IN MEDICINE
- Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
- (2015) S. Gourgou-Bourgade et al. ANNALS OF ONCOLOGY
- Does Cox analysis of a randomized survival study yield a causal treatment effect?
- (2015) Odd O. Aalen et al. LIFETIME DATA ANALYSIS
- Choice of estimand and analysis methods in diabetes trials with rescue medication
- (2015) Björn Holzhauer et al. PHARMACEUTICAL STATISTICS
- Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
- (2014) C. A. Bellera et al. ANNALS OF ONCOLOGY
- Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials)
- (2014) Franck Bonnetain et al. EUROPEAN JOURNAL OF CANCER
- Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
- (2014) Matthew J. Maurer et al. JOURNAL OF CLINICAL ONCOLOGY
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
- (2014) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome
- (2013) Patrick Royston et al. BMC Medical Research Methodology
- Kaplan–Meier curves for survivor causal effects with time-to-event outcomes
- (2013) Yasutaka Chiba Clinical Trials
- Use of historical control data for assessing treatment effects in clinical trials
- (2013) Kert Viele et al. PHARMACEUTICAL STATISTICS
- Adjusting overall survival for treatment switches: commonly used methods and practical application
- (2013) Claire Watkins et al. PHARMACEUTICAL STATISTICS
- Statistical issues and challenges in immuno-oncology
- (2013) Tai-Tsang Chen Journal for ImmunoTherapy of Cancer
- Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: Formal consensus method for the development of guidelines for standardised time-to-event endpoints’ definitions in cancer clinical trials
- (2012) Carine A. Bellera et al. EUROPEAN JOURNAL OF CANCER
- Robust inference in discrete hazard models for randomized clinical trials
- (2012) Vinh Q. Nguyen et al. LIFETIME DATA ANALYSIS
- Estimation of treatment effect under non-proportional hazards and conditionally independent censoring
- (2012) Adam P. Boyd et al. STATISTICS IN MEDICINE
- Dynamic randomization and a randomization model for clinical trials data
- (2012) Lee D. Kaiser STATISTICS IN MEDICINE
- Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival
- (2011) Helgi Birgisson et al. BMC CANCER
- Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803
- (2011) D. Sargent et al. EUROPEAN JOURNAL OF CANCER
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival extrapolation using the poly-Weibull model
- (2011) Nikolaos Demiris et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- The Hazards of Hazard Ratios
- (2009) Miguel A. Hernán EPIDEMIOLOGY
- Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Issues in Using Progression-Free Survival When Evaluating Oncology Products
- (2009) Thomas R. Fleming et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival End Point Reporting in Randomized Cancer Clinical Trials: A Review of Major Journals
- (2008) Simone Mathoulin-Pelissier et al. JOURNAL OF CLINICAL ONCOLOGY
- Endpoints for Assessing Drug Activity in Clinical Trials
- (2008) R. Pazdur ONCOLOGIST
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now